GB0201736D0 - DNA dosage forms - Google Patents

DNA dosage forms

Info

Publication number
GB0201736D0
GB0201736D0 GBGB0201736.6A GB0201736A GB0201736D0 GB 0201736 D0 GB0201736 D0 GB 0201736D0 GB 0201736 A GB0201736 A GB 0201736A GB 0201736 D0 GB0201736 D0 GB 0201736D0
Authority
GB
United Kingdom
Prior art keywords
dna
skin
present
devices
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0201736.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0201736.6A priority Critical patent/GB0201736D0/en
Publication of GB0201736D0 publication Critical patent/GB0201736D0/en
Priority to US10/502,285 priority patent/US20050080028A1/en
Priority to DE60312645T priority patent/DE60312645T2/de
Priority to CA002473717A priority patent/CA2473717A1/en
Priority to AT03700947T priority patent/ATE357219T1/de
Priority to DE60326930T priority patent/DE60326930D1/de
Priority to US10/502,290 priority patent/US20050085434A1/en
Priority to JP2003561581A priority patent/JP2005526016A/ja
Priority to PCT/GB2003/000336 priority patent/WO2003061629A2/en
Priority to AU2003202685A priority patent/AU2003202685A1/en
Priority to JP2003561574A priority patent/JP2005519905A/ja
Priority to CA002473679A priority patent/CA2473679A1/en
Priority to AT03701595T priority patent/ATE427105T1/de
Priority to ES03701595T priority patent/ES2322572T3/es
Priority to EP03700947A priority patent/EP1467711B1/en
Priority to ES03700947T priority patent/ES2285087T3/es
Priority to PCT/GB2003/000282 priority patent/WO2003061636A2/en
Priority to EP03701595A priority patent/EP1467720B1/en
Priority to US11/756,817 priority patent/US20080095854A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0201736.6A 2002-01-25 2002-01-25 DNA dosage forms Ceased GB0201736D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
EP03701595A EP1467720B1 (en) 2002-01-25 2003-01-23 Dna dosage forms
PCT/GB2003/000336 WO2003061629A2 (en) 2002-01-25 2003-01-23 Dna dosage forms
JP2003561574A JP2005519905A (ja) 2002-01-25 2003-01-23 Ｄｎａの製剤
CA002473717A CA2473717A1 (en) 2002-01-25 2003-01-23 Dna dosage forms
AT03700947T ATE357219T1 (de) 2002-01-25 2003-01-23 Darreichungsformen für dns
DE60326930T DE60326930D1 (de) 2002-01-25 2003-01-23 Darreichungsformen für dna
US10/502,290 US20050085434A1 (en) 2002-01-25 2003-01-23 Dna dosage forms
JP2003561581A JP2005526016A (ja) 2002-01-25 2003-01-23 Ｄｎａの投薬形態
US10/502,285 US20050080028A1 (en) 2002-01-25 2003-01-23 Dna dosage forms
AU2003202685A AU2003202685A1 (en) 2002-01-25 2003-01-23 Dna dosage forms
DE60312645T DE60312645T2 (de) 2002-01-25 2003-01-23 Darreichungsformen für dns
CA002473679A CA2473679A1 (en) 2002-01-25 2003-01-23 Dna dosage forms
AT03701595T ATE427105T1 (de) 2002-01-25 2003-01-23 Darreichungsformen fur dna
ES03701595T ES2322572T3 (es) 2002-01-25 2003-01-23 Formas de dosificacicon de adn.
EP03700947A EP1467711B1 (en) 2002-01-25 2003-01-23 Dna dosage forms
ES03700947T ES2285087T3 (es) 2002-01-25 2003-01-23 Formas farmaceuticas de adn.
PCT/GB2003/000282 WO2003061636A2 (en) 2002-01-25 2003-01-23 Dna dosage forms
US11/756,817 US20080095854A1 (en) 2002-01-25 2007-06-01 Dna dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms

Publications (1)

Publication Number Publication Date
GB0201736D0 true GB0201736D0 (en) 2002-03-13

Family

ID=9929749

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0201736.6A Ceased GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms

Country Status (10)

Country Link
US (1) US20050080028A1 (https=)
EP (1) EP1467720B1 (https=)
JP (1) JP2005526016A (https=)
AT (1) ATE427105T1 (https=)
AU (1) AU2003202685A1 (https=)
CA (1) CA2473679A1 (https=)
DE (1) DE60326930D1 (https=)
ES (1) ES2322572T3 (https=)
GB (1) GB0201736D0 (https=)
WO (1) WO2003061636A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
BRPI0415850A (pt) * 2003-10-23 2007-01-02 Alza Corp composição de dna estabilizado para o revestimento de micro projeções
US7591806B2 (en) * 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
EP2272430A1 (en) 2004-08-16 2011-01-12 Functional Microstructures Limited Method of producing a microneedle or microimplant
US8048017B2 (en) * 2005-05-18 2011-11-01 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US8043250B2 (en) * 2005-05-18 2011-10-25 Nanomed Devices, Inc. High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
CN101227940A (zh) * 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 微阵列装置
CA2629193C (en) 2005-11-18 2016-03-29 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US10525246B2 (en) 2006-12-22 2020-01-07 Nanomed Skincare, Inc. Microdevice and method for transdermal delivery and sampling of active substances
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
KR101314091B1 (ko) * 2011-07-26 2013-10-04 연세대학교 산학협력단 치료 부위내 경피 유전자 전달을 위한 일렉트로 마이크로니들 집적체 및 이의 제조방법
JP2013052202A (ja) * 2011-09-01 2013-03-21 Kosumedei Seiyaku Kk Ｄｎａワクチンマイクロニードル
US10064960B2 (en) * 2011-11-25 2018-09-04 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE235558T1 (de) * 1989-06-26 2003-04-15 Powderject Vaccines Inc Transformation von tierischen somatischen zellen mittels partikeln
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
AU705889B2 (en) * 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ES2208687T3 (es) * 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
EP0906110B1 (en) * 1996-04-26 2004-12-22 Merck & Co., Inc. Dna vaccine formulations
EP1100579B1 (en) * 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6713291B2 (en) * 1999-01-28 2004-03-30 Alan D. King Electrodes coated with treating agent and uses thereof
EP1163024B1 (en) * 1999-01-28 2003-12-17 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
EP1299087A1 (en) * 2000-07-07 2003-04-09 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
NZ529029A (en) * 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating

Also Published As

Publication number Publication date
EP1467720A2 (en) 2004-10-20
ATE427105T1 (de) 2009-04-15
US20050080028A1 (en) 2005-04-14
DE60326930D1 (de) 2009-05-14
ES2322572T3 (es) 2009-06-23
EP1467720B1 (en) 2009-04-01
WO2003061636A3 (en) 2003-11-27
CA2473679A1 (en) 2003-07-31
AU2003202685A1 (en) 2003-09-02
WO2003061636A2 (en) 2003-07-31
JP2005526016A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
GB0201736D0 (en) DNA dosage forms
AU2003295614A8 (en) Delivery of pharmaceutical agents via the human insulin receptor
BRPI0416132A (pt) sistema e método para liberação de vacina transdérmica
WO2007108988A3 (en) Infusion device with pressurizable liquid medicament chamber
IL183606A (en) Medical device
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
BR0212434A (pt) Dispositivos médicos contendo análogos de rapamicina
DE602005008404D1 (de) Medikamentenabgabevorrichtung
MXPA05005315A (es) Dispositivos medicos que incorporan rapamicina deuterizada para la administracion controlada de la misma.
AU2003297848A1 (en) High viscosity liquid controlled delivery system and medical or surgical device
PT1301238E (pt) Agulhas revestidas com vacina
WO2006118945A8 (en) Local delivery of an active agent from an orthopedic implant
WO2006084139A3 (en) An implantable interferon-containing device
TW200505402A (en) Ophthalmic drug delivery device
WO2009029958A3 (en) Implantable delivery device
WO2008027371A3 (en) Low profile bioactive agent delivery device
BRPI0415466A (pt) método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos
BRPI0707845A8 (pt) dispositivo de envio de droga
WO2005120393A3 (en) Implantable device for drug delivery and improved visibility
AR046696A1 (es) Aplicador auto-accionante para grupo de microproyecciones
IL169287A (en) Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
BRPI0415986A (pt) método e aparelho para reduzir a incidência do uso de tabaco
ITMI20000300A0 (it) Nebulizzatore medico per liquido da utilizzare nella terapia respiratoria e altre applicazioni
ATE509637T1 (de) Temperaturgesteuerte verabreichungssysteme

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)